Related Experiment Video
Updated: May 12, 2025
Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
Published on: February 3, 2021
[Invasive treatment of chronic coronary syndrome]
Insights
The 2024 European Society of Cardiology guidelines update chronic coronary syndrome treatment, emphasizing myocardial revascularization alongside optimal medical therapy. The choice between percutaneous coronary intervention and coronary artery bypass surgery is individualized based on disease complexity and patient factors.
Area of Science:
- Cardiology
- Clinical Guidelines
Background:
- Chronic coronary syndrome management requires updated evidence-based recommendations.
- Previous guidelines for myocardial revascularization were established in 2018.
Purpose of the Study:
- To present the 2024 European Society of Cardiology guidelines for chronic coronary syndrome.
- To update recommendations on myocardial revascularization based on current scientific evidence.
Main Methods:
- Comprehensive review of the latest scientific evidence.
- Integration of new data into treatment strategies for chronic coronary syndrome.
- Focus on pharmacological and invasive therapies, including myocardial revascularization.
Main Results:
- Updated guidelines provide a framework for prevention, diagnostics, and therapy.
- Myocardial revascularization is confirmed as key for symptom relief and improved outcomes.
- Decision-making for revascularization considers disease complexity, comorbidities, and patient preferences.
Conclusions:
- Individualized treatment approaches and risk-benefit assessments are crucial.
- The guidelines offer an evidence-based approach to complex decision-making in chronic coronary syndrome.
- Optimal pharmacological therapy remains a cornerstone, with revascularization as an adjunct.
Abstract:
The 2024 guidelines of the European Society of Cardiology for the treatment of chronic coronary syndrome provide a comprehensive overview covering prevention, diagnostics, as well as pharmacological and invasive therapies. Based on the latest scientific evidence, the guidelines for myocardial revascularization, valid since 2018, have been updated, and treatment recommendations have been adjusted accordingly. Myocardial revascularization, as an adjunct to optimal pharmacological therapy, remains a key treatment strategy for symptom relief, as well as for improving quality of life and long-term clinical outcomes in patients with chronic coronary syndrome. The decision between percutaneous coronary intervention and coronary artery bypass surgery depends on the anatomical complexity and functional severity of coronary artery disease, as well as comorbidities, patient preferences, and expectations. A careful risk-benefit assessment and an individualized treatment approach are essential to ensure optimal care for each patient. The current guidelines provide an evidence-based framework for this complex decision-making process.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System